Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.

Monthly Archives: August 2012

29 08, 2012

Dr. Bradner weighs-in on JQ1 debate

Tags: , , |8 Comments

Two weeks ago I re-visited the promising new anti-cancer therapy, JQ1, after learning that JQ1 may also hold the key to male contraception. If you haven't been following along,  last summer a group of Dana-Farber Cancer Institute scientists reported that they had "successfully disrupted the function of a cancer gene involved in the formation of most

28 08, 2012

Supplements that enhance Velcade’s performance

Tags: , , , , , |24 Comments

Before I get started, I have been receiving emails and comments defending glucosamine. I understand!  I had been taking glucosamine for years.  It helped my knee pain improve measurably.  But Danny Parker convinced me to drop-it-off my long--and now shrinking--supplement list. Danny emailed me several times yesterday.  Allow me to share a few of his

27 08, 2012

Growing list of supplements that myeloma patients should avoid

Tags: , , , , , |2 Comments

Some supplements should be avoided by anyone with multple myeloma, not just those taking Velcade. Here's a specific example.  Antioxidants are one of nature's miracle compounds.  They help protect healthy cells and repair damaged ones. A day doesn't go by where I don't hear about a new "miracle" antioxidant producing plant or berry--usually found deep

25 08, 2012

Alpha Lipoic Acid not good for myeloma patients

Tags: , , , , , |13 Comments

Alpha lipoic acid is one of the best--if not the best--anti-neuropathy supplements available.  Velcade (bortezomib) causes peripheral neuropathy (PN) in most patients that use it. So understandably, many cancer centers that treat multiple myeloma are recommending patients take alpha lipoic acid (ALA) to help minimize Velcade induced PN. But apparently, alpha lipoic acid shouldn't be

24 08, 2012

What causes multiple myeloma? Is there a genetic link?

Tags: |12 Comments

Until recently, most myeloma experts have agreed that there is no nutritional or genetic familial link back to multiple myeloma.  In other words, there is/was no proof that what we ate--or who we were related to--could cause bone marrow cancer. Earlier this summer I blogged about possible nutritional causes: Proof of nutritional link to multiple

19 08, 2012

This week’s inspirational patient story: Tom Whittaker


As you may already know, I have heard from a number of readers that would like to hear from older myeloma patients/survivors. I found 74 year old Tom Whittaker's story to be fascinating.  Tom's story begins as a classic case of miss-diagnosis.  But what inspired me was the way he overcame some serious surgical complications. 

14 08, 2012

I make my case: Dump multiple myeloma!

Tags: |2 Comments

What's in a name?  Yesterday I wrote this: So who the heck came-up with the name “multiple myeloma?”  Heck, even dropping the “multiple” part makes more sense.  “Myeloma.”  Not so bad. But while I was speaking to the Twin Cities Multiple Myeloma Support Group (a bit long, but a clearly descriptive name) Saturday, I suggested

13 08, 2012

Multiple myeloma. What a ridiculous name!

Tags: , , |8 Comments

Yesterday I passed-along the new name that was selected for Millennium's experimental proteasome inhibitor, MLN9708:  ixazomib Is "ixazomib" a good choice?  Who knows? But I will suggest a name that isn't very good:  multiple myeloma. Isn't very good?  IT STINKS! I'm an educated guy.  A former business owner and teacher, I have a Masters degree--yet

12 08, 2012

Millennium Pharmaceutical’s MLN9708 has a name: ixazomib

Tags: , , , |0 Comments

Remember this name: ixazomib (ix az' oh mib) Originally dubbed MLN9708, Millennium Pharmaceutical's experimental proteasome inhibitor has as much potential to help patients as any new anti-myeloma drug in the research pipeline. So don’t you think that it deserved a name? To clarify, this isn’t the new drug’s trade name. Think about Onyx’s new proteasome